Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smooth muscle cells

Yoshiaki Ito, Osamu Kozawa, Haruhiko Tokuda, Atsushi Suzuki, Yasuko Watanabe, Jun Kotoyori, Yutaka Oiso

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

It is well-known that atherosclerotic change and hypertension are common manifestations in patients with glucocorticoid excess. We previously reported that pituitary adenylate cyclase activating polypeptide (PACAP), prostaglandin E2 (PGE2) and carbacyclin, a stable analog of prostacyclin, have suppressive effects on vasopressin-induced DNA synthesis of rat aortic smooth muscle cells through cAMP production (Murase et al., J. Hypertens., 10 (1992) 1505; Oiso et al., Biochem. Cell. Biol., 71 (1993) 156). In the present study, we investigated the effect of glucocorticoid on cAMP production induced by PACAP, PGE2 and carbacyclin in aortic smooth muscle cells. The pretreatment with dexamethasone significantly inhibited cAMP accumulation induced by these vasoactive agents in a dose dependent manner in the range between 10 pM and 10 nM. These inhibitory effects of dexamethasone were dependent on the time of pretreatment up to 8 h. Dexamethasone inhibited CAMP accumulation induced by NaF, a GTP-binding protein activator, and forskolin which directly activates adenylate cyclase. Moreover, forskolin-induced adenylate cyclase activity was significantly reduced in membranes prepared from the cells treated with dexamethasone. These results strongly suggest that glucocorticoid inhibits CAMP production induced by vasoactive agents in primary cultured rat aortic smooth muscle cells and the inhibitory effect is exerted at the level of adenylate cyclase.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalAtherosclerosis
Volume110
Issue number1
DOIs
Publication statusPublished - 30-09-1994
Externally publishedYes

Fingerprint

Dexamethasone
Glucocorticoids
Smooth Muscle Myocytes
Adenylyl Cyclases
Pituitary Adenylate Cyclase-Activating Polypeptide
Colforsin
Dinoprostone
Epoprostenol
Vasopressins
GTP-Binding Proteins
Cell Membrane
Hypertension
DNA
carboprostacyclin

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ito, Yoshiaki ; Kozawa, Osamu ; Tokuda, Haruhiko ; Suzuki, Atsushi ; Watanabe, Yasuko ; Kotoyori, Jun ; Oiso, Yutaka. / Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smooth muscle cells. In: Atherosclerosis. 1994 ; Vol. 110, No. 1. pp. 69-76.
@article{89079905bc394b429263fda8d65a87e5,
title = "Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smooth muscle cells",
abstract = "It is well-known that atherosclerotic change and hypertension are common manifestations in patients with glucocorticoid excess. We previously reported that pituitary adenylate cyclase activating polypeptide (PACAP), prostaglandin E2 (PGE2) and carbacyclin, a stable analog of prostacyclin, have suppressive effects on vasopressin-induced DNA synthesis of rat aortic smooth muscle cells through cAMP production (Murase et al., J. Hypertens., 10 (1992) 1505; Oiso et al., Biochem. Cell. Biol., 71 (1993) 156). In the present study, we investigated the effect of glucocorticoid on cAMP production induced by PACAP, PGE2 and carbacyclin in aortic smooth muscle cells. The pretreatment with dexamethasone significantly inhibited cAMP accumulation induced by these vasoactive agents in a dose dependent manner in the range between 10 pM and 10 nM. These inhibitory effects of dexamethasone were dependent on the time of pretreatment up to 8 h. Dexamethasone inhibited CAMP accumulation induced by NaF, a GTP-binding protein activator, and forskolin which directly activates adenylate cyclase. Moreover, forskolin-induced adenylate cyclase activity was significantly reduced in membranes prepared from the cells treated with dexamethasone. These results strongly suggest that glucocorticoid inhibits CAMP production induced by vasoactive agents in primary cultured rat aortic smooth muscle cells and the inhibitory effect is exerted at the level of adenylate cyclase.",
author = "Yoshiaki Ito and Osamu Kozawa and Haruhiko Tokuda and Atsushi Suzuki and Yasuko Watanabe and Jun Kotoyori and Yutaka Oiso",
year = "1994",
month = "9",
day = "30",
doi = "10.1016/0021-9150(94)90069-8",
language = "English",
volume = "110",
pages = "69--76",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smooth muscle cells. / Ito, Yoshiaki; Kozawa, Osamu; Tokuda, Haruhiko; Suzuki, Atsushi; Watanabe, Yasuko; Kotoyori, Jun; Oiso, Yutaka.

In: Atherosclerosis, Vol. 110, No. 1, 30.09.1994, p. 69-76.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smooth muscle cells

AU - Ito, Yoshiaki

AU - Kozawa, Osamu

AU - Tokuda, Haruhiko

AU - Suzuki, Atsushi

AU - Watanabe, Yasuko

AU - Kotoyori, Jun

AU - Oiso, Yutaka

PY - 1994/9/30

Y1 - 1994/9/30

N2 - It is well-known that atherosclerotic change and hypertension are common manifestations in patients with glucocorticoid excess. We previously reported that pituitary adenylate cyclase activating polypeptide (PACAP), prostaglandin E2 (PGE2) and carbacyclin, a stable analog of prostacyclin, have suppressive effects on vasopressin-induced DNA synthesis of rat aortic smooth muscle cells through cAMP production (Murase et al., J. Hypertens., 10 (1992) 1505; Oiso et al., Biochem. Cell. Biol., 71 (1993) 156). In the present study, we investigated the effect of glucocorticoid on cAMP production induced by PACAP, PGE2 and carbacyclin in aortic smooth muscle cells. The pretreatment with dexamethasone significantly inhibited cAMP accumulation induced by these vasoactive agents in a dose dependent manner in the range between 10 pM and 10 nM. These inhibitory effects of dexamethasone were dependent on the time of pretreatment up to 8 h. Dexamethasone inhibited CAMP accumulation induced by NaF, a GTP-binding protein activator, and forskolin which directly activates adenylate cyclase. Moreover, forskolin-induced adenylate cyclase activity was significantly reduced in membranes prepared from the cells treated with dexamethasone. These results strongly suggest that glucocorticoid inhibits CAMP production induced by vasoactive agents in primary cultured rat aortic smooth muscle cells and the inhibitory effect is exerted at the level of adenylate cyclase.

AB - It is well-known that atherosclerotic change and hypertension are common manifestations in patients with glucocorticoid excess. We previously reported that pituitary adenylate cyclase activating polypeptide (PACAP), prostaglandin E2 (PGE2) and carbacyclin, a stable analog of prostacyclin, have suppressive effects on vasopressin-induced DNA synthesis of rat aortic smooth muscle cells through cAMP production (Murase et al., J. Hypertens., 10 (1992) 1505; Oiso et al., Biochem. Cell. Biol., 71 (1993) 156). In the present study, we investigated the effect of glucocorticoid on cAMP production induced by PACAP, PGE2 and carbacyclin in aortic smooth muscle cells. The pretreatment with dexamethasone significantly inhibited cAMP accumulation induced by these vasoactive agents in a dose dependent manner in the range between 10 pM and 10 nM. These inhibitory effects of dexamethasone were dependent on the time of pretreatment up to 8 h. Dexamethasone inhibited CAMP accumulation induced by NaF, a GTP-binding protein activator, and forskolin which directly activates adenylate cyclase. Moreover, forskolin-induced adenylate cyclase activity was significantly reduced in membranes prepared from the cells treated with dexamethasone. These results strongly suggest that glucocorticoid inhibits CAMP production induced by vasoactive agents in primary cultured rat aortic smooth muscle cells and the inhibitory effect is exerted at the level of adenylate cyclase.

UR - http://www.scopus.com/inward/record.url?scp=0028061575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028061575&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(94)90069-8

DO - 10.1016/0021-9150(94)90069-8

M3 - Article

C2 - 7857372

AN - SCOPUS:0028061575

VL - 110

SP - 69

EP - 76

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -